A rifaximin klinikai és farmakológiai jellemzoi, nem felszívódó antibiotikum az intestinalis megbetegedések kezelésére.

Translated title of the contribution: Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The authors report pharmacokinetics and indications of rifaximin and the results of clinical studies. Rifaximin has a large antibacterial spectrum with a good therapeutic effect on both gram positive and gram negative aerob and anaerob bacteria. Practically there is no absorption (<1%) following oral administration with a high concentration in gastrointestinal mucosa (8000 microg/g). No increase in absorption can be detected in intestinal damage caused by inflammatory bowel disease. The remarkable safety profile of rifaximin is due to its negligible quality of absorption. According to the clinical studies rifaximin could be an adequate therapeutic approach in all gastrointestinal diseases and interventions when antibacterial therapy is needed.

Original languageHungarian
Pages (from-to)2177-2181
Number of pages5
JournalOrvosi Hetilap
Volume145
Issue number43
Publication statusPublished - Oct 24 2004

Fingerprint

rifaximin
Pharmacology
Anti-Bacterial Agents
Gastrointestinal Diseases
Therapeutic Uses
Therapeutics
Inflammatory Bowel Diseases
Oral Administration
Mucous Membrane
Pharmacokinetics
Bacteria
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{ae609026cd42412ebcc0d4221e87a96e,
title = "A rifaximin klinikai {\'e}s farmakol{\'o}giai jellemzoi, nem felsz{\'i}v{\'o}d{\'o} antibiotikum az intestinalis megbeteged{\'e}sek kezel{\'e}s{\'e}re.",
abstract = "The authors report pharmacokinetics and indications of rifaximin and the results of clinical studies. Rifaximin has a large antibacterial spectrum with a good therapeutic effect on both gram positive and gram negative aerob and anaerob bacteria. Practically there is no absorption (<1{\%}) following oral administration with a high concentration in gastrointestinal mucosa (8000 microg/g). No increase in absorption can be detected in intestinal damage caused by inflammatory bowel disease. The remarkable safety profile of rifaximin is due to its negligible quality of absorption. According to the clinical studies rifaximin could be an adequate therapeutic approach in all gastrointestinal diseases and interventions when antibacterial therapy is needed.",
author = "B. Gasztonyi and B. Hunyady",
year = "2004",
month = "10",
day = "24",
language = "Hungarian",
volume = "145",
pages = "2177--2181",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "43",

}

TY - JOUR

T1 - A rifaximin klinikai és farmakológiai jellemzoi, nem felszívódó antibiotikum az intestinalis megbetegedések kezelésére.

AU - Gasztonyi, B.

AU - Hunyady, B.

PY - 2004/10/24

Y1 - 2004/10/24

N2 - The authors report pharmacokinetics and indications of rifaximin and the results of clinical studies. Rifaximin has a large antibacterial spectrum with a good therapeutic effect on both gram positive and gram negative aerob and anaerob bacteria. Practically there is no absorption (<1%) following oral administration with a high concentration in gastrointestinal mucosa (8000 microg/g). No increase in absorption can be detected in intestinal damage caused by inflammatory bowel disease. The remarkable safety profile of rifaximin is due to its negligible quality of absorption. According to the clinical studies rifaximin could be an adequate therapeutic approach in all gastrointestinal diseases and interventions when antibacterial therapy is needed.

AB - The authors report pharmacokinetics and indications of rifaximin and the results of clinical studies. Rifaximin has a large antibacterial spectrum with a good therapeutic effect on both gram positive and gram negative aerob and anaerob bacteria. Practically there is no absorption (<1%) following oral administration with a high concentration in gastrointestinal mucosa (8000 microg/g). No increase in absorption can be detected in intestinal damage caused by inflammatory bowel disease. The remarkable safety profile of rifaximin is due to its negligible quality of absorption. According to the clinical studies rifaximin could be an adequate therapeutic approach in all gastrointestinal diseases and interventions when antibacterial therapy is needed.

UR - http://www.scopus.com/inward/record.url?scp=16544376335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544376335&partnerID=8YFLogxK

M3 - Article

C2 - 15575494

AN - SCOPUS:16544376335

VL - 145

SP - 2177

EP - 2181

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 43

ER -